Precigen (NASDAQ:PGEN) Hits New 12-Month High After Analyst Upgrade

Precigen, Inc. (NASDAQ:PGEN)’s share price hit a new 52-week high on Thursday after Wall Street Zen upgraded the stock from a hold rating to a strong-buy rating. The company traded as high as $7.23 and last traded at $6.89, with a volume of 16909114 shares changing hands. The stock had previously closed at $6.53.

A number of other equities analysts have also recently issued reports on PGEN. HC Wainwright raised their price objective on shares of Precigen from $14.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday. Zacks Research raised Precigen from a “hold” rating to a “strong-buy” rating in a research note on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of Precigen in a research report on Friday, July 17th. Citigroup reissued an “outperform” rating on shares of Precigen in a research note on Thursday, May 14th. Finally, Citizens Jmp raised their target price on Precigen from $9.00 to $11.00 and gave the stock a “market outperform” rating in a report on Thursday, May 14th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Precigen presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.50.

Insider Buying and Selling

In related news, CFO Harry Jr. Thomasian sold 171,429 shares of the stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $5.53, for a total transaction of $948,002.37. Following the completion of the transaction, the chief financial officer directly owned 354,535 shares of the company’s stock, valued at approximately $1,960,578.55. This represents a 32.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Rutul R. Shah sold 42,924 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $5.85, for a total value of $251,105.40. Following the completion of the transaction, the chief operating officer owned 497,751 shares of the company’s stock, valued at approximately $2,911,843.35. This represents a 7.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 989,239 shares of company stock worth $5,472,960 over the last 90 days. 41.40% of the stock is currently owned by insiders.

Precigen News Roundup

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: Strong earnings and commercial momentum: Precigen reported second-quarter 2026 revenue of approximately $55 million, far exceeding analyst expectations, and earnings of $0.05 per share versus the expected $0.01 loss. Revenue was driven largely by PAPZIMEOS, whose sales reportedly doubled sequentially to $53.1 million. The company also achieved quarterly profitability, supporting the view that its commercial business is scaling rapidly. Precigen Q2 2026 Earnings Call Highlights
• Positive Sentiment: More favorable analyst outlook: HC Wainwright maintained a Buy rating and an $18 price target while raising its Q3 2026 EPS forecast to $0.05 from $0.01 and its full-year 2026 forecast to $0.14 from $0.02. The firm also lifted its FY2027 estimate to $0.44 from $0.34, reflecting expectations for continued profitability and growth. HC Wainwright Precigen Estimates
• Positive Sentiment: Additional bullish ratings: Zacks Research upgraded Precigen from “Hold” to “Strong Buy.” Separately, an investment analysis cited PAPZIMEOS’ FDA approval for recurrent respiratory papillomatosis, seven years of U.S. market exclusivity, possible European approval, and advancement of the PRGN-2009 program as potential drivers of future revenue. Zacks Research
• Neutral Sentiment: HC Wainwright’s projections imply a sharp earnings ramp, reaching $0.71 EPS in FY2028 and $1.49 EPS in FY2030. However, the firm made a small reduction to its FY2028 estimate, from $0.72 to $0.71, indicating that longer-term forecasts remain subject to execution risk.

Institutional Trading of Precigen

Several institutional investors and hedge funds have recently added to or reduced their stakes in PGEN. BlackRock Inc. bought a new stake in shares of Precigen in the 2nd quarter valued at about $97,737,000. State Street Corp grew its holdings in Precigen by 141.1% during the fourth quarter. State Street Corp now owns 10,824,860 shares of the biotechnology company’s stock worth $45,248,000 after purchasing an additional 6,335,033 shares during the period. SymBiosis Capital Partners LLC bought a new position in Precigen during the fourth quarter worth about $12,540,000. Bank of America Corp DE increased its position in Precigen by 201.1% during the third quarter. Bank of America Corp DE now owns 2,505,992 shares of the biotechnology company’s stock worth $8,245,000 after buying an additional 1,673,731 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its position in Precigen by 196.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,173,933 shares of the biotechnology company’s stock worth $9,087,000 after buying an additional 1,440,446 shares during the last quarter. 33.51% of the stock is owned by institutional investors.

Precigen Stock Up 4.6%

The company has a quick ratio of 4.12, a current ratio of 4.58 and a debt-to-equity ratio of 2.15. The firm has a 50 day simple moving average of $5.23 and a 200-day simple moving average of $4.50. The stock has a market cap of $2.58 billion, a P/E ratio of -6.95 and a beta of 1.02.

Precigen (NASDAQ:PGEN) last issued its earnings results on Tuesday, August 4th. The biotechnology company reported $0.05 EPS for the quarter, topping the consensus estimate of ($0.01) by $0.06. The company had revenue of $54.98 million during the quarter, compared to the consensus estimate of $27.98 million. Precigen had a positive return on equity of 423.75% and a negative net margin of 183.98%.Precigen’s quarterly revenue was up 6322.7% compared to the same quarter last year. On average, equities research analysts forecast that Precigen, Inc. will post 0.05 earnings per share for the current fiscal year.

About Precigen

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.